• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Scholar Rock Holding Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    5/7/26 7:10:21 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SRRK alert in real time by email
    Scholar Rock Holding Corporation_May 7, 2026
    0001727196false00017271962026-05-072026-05-07

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ​

    ​

    FORM 8-K

    ​

    ​

    CURRENT REPORT

    ​

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    ​

    Date of Report (Date of earliest event Reported): May 7, 2026

    ​

    Scholar Rock Holding Corporation

    (Exact Name of Registrant as Specified in Charter)

    ​

    ​

    ​

    ​

    ​

    ​

    Delaware

      ​ ​ ​

    001-38501

      ​ ​ ​

    82-3750435

    (State or Other Jurisdiction of
    Incorporation)

    ​

    (Commission File Number)

    ​

    (I.R.S. Employer Identification Number)

    ​

    301 Binney Street, 3rd Floor, Cambridge, MA 02142

    (Address of Principal Executive Offices) (Zip Code)

    ​

    (857) 259-3860

    (Registrant’s telephone number, including area code)

    ​

    (Former name or former address, if changed since last report)

    ​

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ​

    ​

    ​

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ​

    ​

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ​

    ​

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ​

    ​

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    Title of each class

    Trading Symbol(s)

    Name of each exchange on which registered

    Common Stock, par value $0.001 per share

    SRRK

    The Nasdaq Global Select Market

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    ​

    ​

    ​

    ​

    Item 2.02. Results of Operations and Financial Condition.

    ​

    On May 7, 2026, Scholar Rock Holding Corporation (the “Company”) issued a press release announcing its financial and operating results for the quarter ended March 31, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.

    ​

    The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

    ​

    Item 7.01. Regulation FD Disclosure.

    ​

    The Company will utilize slides during its conference call scheduled for 8:00 am ET on May 7, 2026 to announce its financial and operating results for the fiscal quarter ended March 31, 2026 and to provide a business update. A copy of the slides is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01 as if fully set forth herein.

    ​

    The information in this Current Report on Form 8-K and Exhibits 99.1 and 99.2 attached hereto are intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

    ​

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit
    No.

      ​ ​

    Description

     

     

    99.1

     

    Press Release issued by the Company on May 7, 2026, furnished hereto.

    99.2

    ​

    Scholar Rock Holding Corporation Corporate Presentation dated May 7, 2026, furnished hereto.

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

    ​

    ​

    ​

    ​

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Scholar Rock Holding Corporation

     

     

     

    Date: May 7, 2026

    By:

    /s/ Junlin Ho

     

     

    Junlin Ho

     

     

    General Counsel & Corporate Secretary

    ​

    ​

    ​

    Get the next $SRRK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SRRK

    DatePrice TargetRatingAnalyst
    4/21/2026$62.00Buy
    Canaccord Genuity
    1/9/2026$55.00Buy
    Citigroup
    11/18/2025$42.00Outperform
    Wolfe Research
    10/9/2025$53.00Buy
    BofA Securities
    9/17/2025$45.00Overweight
    Barclays
    9/15/2025$51.00Outperform
    Leerink Partners
    8/21/2025$50.00Buy
    Jefferies
    7/30/2025$53.00Strong Buy
    Raymond James
    More analyst ratings

    $SRRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

    Scholar Rock (NASDAQ:SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 9, 2026 at 10:00 a.m. ET. A live webcast of the event will be available under the "Events and Presentations" page within the Investors section of the Scholar Rock website at http://investors.scholarrock.com. A replay of the webcast will be availabl

    5/26/26 9:30:00 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference

    Scholar Rock (NASDAQ:SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the 2026 Jefferies Global Healthcare Conference in New York, NY on Wednesday, June 3, 2026 at 11:40 a.m. ET. A live webcast of the event will be available under the "Events and Presentations" page within the Investors section of the Scholar Rock website at http://investors.scholarrock.com. A replay of the webcast will be available for

    5/20/26 8:00:00 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the company granted inducement equity awards covering an aggregate of 38,481 shares of its common stock to six newly hired employees, consisting of inducement stock options to purchase an aggregate of 12,061 shares of common stock and inducement restricted stock units, covering an aggregate of 26,420 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the "Plan") and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is used

    5/15/26 4:15:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Akkaraju Srinivas bought $1,181,634 worth of shares (29,599 units at $39.92) and exercised 1,064,804 in-the-money shares at a strike of $7.35 (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    12/16/25 9:07:57 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Akkaraju Srinivas bought $18,807,352 worth of shares (500,439 units at $37.58) (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    10/7/25 8:59:19 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Akkaraju Srinivas bought $15,000,000 worth of shares (2,189,781 units at $6.85) (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    10/18/23 5:46:02 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Scholar Rock with a new price target

    Canaccord Genuity initiated coverage of Scholar Rock with a rating of Buy and set a new price target of $62.00

    4/21/26 7:34:59 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Citigroup initiated coverage on Scholar Rock with a new price target

    Citigroup initiated coverage of Scholar Rock with a rating of Buy and set a new price target of $55.00

    1/9/26 9:07:37 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wolfe Research initiated coverage on Scholar Rock with a new price target

    Wolfe Research initiated coverage of Scholar Rock with a rating of Outperform and set a new price target of $42.00

    11/18/25 8:27:21 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $SRRK
    SEC Filings

    View All

    Director Burow Kristina exercised 89,800 shares at a strike of $9.14, increasing direct ownership by 426% to 110,871 units (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    4/24/26 4:05:11 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Woods Keith

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    4/20/26 6:12:15 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Vaishnaw Akshay

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    4/20/26 6:10:16 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock Holding Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Scholar Rock Holding Corp (0001727196) (Filer)

    6/4/26 7:21:48 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Scholar Rock Holding Corporation

    SCHEDULE 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    5/15/26 4:16:37 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Scholar Rock Holding Corporation

    SCHEDULE 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    5/15/26 10:07:47 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Leadership Updates

    Live Leadership Updates

    View All

    Scholar Rock Appoints Caryn Parlavecchio as Chief Human Resources Officer

    - Former Vice President and Global HR Head of Oncology and Pharma Development at Novartis brings extensive leadership experience focused on talent, culture, and diversity Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Caryn Parlavecchio as Chief Human Resources Officer. She will join the executive team, bringing more than 20 years of experience as a senior leader and strategic executive in the biotechnology and pharmaceutical industries. This press release features multimedia. View the full release here: https://www.businesswire.co

    8/16/21 4:05:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Financials

    Live finance-specific insights

    View All

    Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

    Scholar Rock (NASDAQ:SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 9, 2026 at 10:00 a.m. ET. A live webcast of the event will be available under the "Events and Presentations" page within the Investors section of the Scholar Rock website at http://investors.scholarrock.com. A replay of the webcast will be availabl

    5/26/26 9:30:00 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference

    Scholar Rock (NASDAQ:SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the 2026 Jefferies Global Healthcare Conference in New York, NY on Wednesday, June 3, 2026 at 11:40 a.m. ET. A live webcast of the event will be available under the "Events and Presentations" page within the Investors section of the Scholar Rock website at http://investors.scholarrock.com. A replay of the webcast will be available for

    5/20/26 8:00:00 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the company granted inducement equity awards covering an aggregate of 38,481 shares of its common stock to six newly hired employees, consisting of inducement stock options to purchase an aggregate of 12,061 shares of common stock and inducement restricted stock units, covering an aggregate of 26,420 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the "Plan") and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is used

    5/15/26 4:15:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

    SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    11/14/24 9:00:58 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

    SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    11/14/24 7:24:55 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

    SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    11/14/24 1:22:38 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care